Quick answers
- What is Albendazole used for?
- The FDA-approved label (Albenza, Amneal Pharmaceuticals LLC, September 23, 2019) says: “ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Albendazole have a boxed warning?
- No. None of the 10 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Albendazole?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Albendazole been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Albendazole?
- 10 companies list prescription products of Albendazole in the FDA NDC Directory, including Actavis Pharma, Inc., Edenbridge Pharmaceuticals LLC. and Dr.Reddys Laboratories Inc.
What Albendazole is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium. Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus. …
— FDA label: Albenza, Amneal Pharmaceuticals LLC, effective September 23, 2019. Read the full label on DailyMed →
The FDA has 10 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 10 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet |
|---|---|
| Route | Oral |
| Prescription products | 10 in the FDA NDC Directory |
| Brand names | Albenza |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| albendazole 200 mg tablet | Generic | $4.13 per tablet |
| albendazole 200 mg tablet, film coated | Generic | $4.13 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Actavis Pharma, Inc.1 product
- Edenbridge Pharmaceuticals LLC.1 product
- Dr.Reddys Laboratories Inc1 product
- Alembic Pharmaceuticals Limited1 product
- Bryant Ranch Prepack1 product
- Novadoz Pharmaceuticals LLC1 product
- Amneal Pharmaceuticals of New York LLC1 product
- Amneal Pharmaceuticals LLC1 product
- Golden State Medical Supply, Inc.1 product
- Alembic Pharmaceuticals Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA020666 ALBENZA | Impax Labs Inc | June 11, 1996 | 7, latest July 11, 2019 2019: Labeling · 2018: Labeling · 2017: Labeling |
Generic approvals (5)
- ANDA211117Edenbridge Pharms · May 14, 2019
- ANDA208094Actavis Elizabeth · May 20, 2019
- ANDA213435Msn · January 22, 2021
- ANDA211034DR Reddys · January 26, 2021
- ANDA215652Alembic · September 4, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 199672, 211148 |
|---|---|
| SPL set ID of the quoted label | 1977a867-0ee1-44c0-8da3-fe59c48699f5 |
| FDA labels (SPL) | 10 |
| FDA applications | NDA020666, 5 ANDA |
| Active ingredients (FDA) | ALBENDAZOLE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Albenza, Amneal Pharmaceuticals LLC, effective September 23, 2019; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →